Future Journal of Pharmaceuticals and Health Sciences

Formulation and evaluation of immediate and controlled release rizatriptan benzoate pellets

K.V. Swathi Krishna — 2025-01-06

The goal of the current study is to formulate and evaluate Rizatriptan benzoate pellets using sodium alginate, Methylcellulose, and carbopol in varying ratios as release-retarding polymers using the solution/suspension layer technique. This will prolong the drug's release, reduce the peak and valley effect in the plasma, and offer patients convenience. For a maximum of six months, the formulation undergoing stability studies has been examined for drug content and in vitro dissolution. The estimated shelf life of the reagent was ascertained by comparing the computed and actual assays. None of the tested parameters of the formulations showed any apparent changes, indicating that the formulations were stable. Stability tests were carried out for six months at 250C/60% and 400C/75% RH for the optimal formulation of F12 every two months. By comparing the calculated and observed assays, the assay's expected shelf life was 14 months. According to the results, formulation F12 was stable because there were no appreciable changes in the drug content analysis or in-vitro dissolution research.

A pharmacoeconomic comparison of atorvastatin vs rosuvastatin in treatment of acute coronary syndrome in tertiary care hospital

P. Kashif Suleman — 2025-01-04

Background: Pharmacoeconomics is a scientific discipline that evaluates the value of one pharmaceutical drug or therapy compared to another. It analyses the costs and effects of pharmaceutical products. The treatment and prevention of acute coronary syndrome (ACS) incur high costs, and the growing demand for clinical interventions further strains healthcare resources. Identifying cost-effective therapeutic options is vital for optimising resource utilisation.Objective: This study aimed to identify the most cost-effective drug combination for ACS treatment and reduce patients’ financial burden.Methodology: A prospective observational study was conducted over two months at Madhu Hospital, Adoni, involving 80 patients aged 18–80 years diagnosed with ACS. Participants were randomly assigned into two groups: Group A received atorvastatin (40 mg) and Group B received rosuvastatin (20 mg), both administered orally once daily. Lipid profiles were monitored monthly.Results: A statistically significant reduction in abnormal lipid profiles was observed in both groups. However, atorvastatin demonstrated greater cost-effectiveness compared to rosuvastatin. Monthly follow-ups confirmed these findings.Conclusion: This pharmacoeconomic analysis concluded that atorvastatin is a more cost-effective option than rosuvastatin for treating ACS.

Evaluating the prevalence, identifying triggers, and classifying the triggers within the patients suffering from migraine

R Gautham Chakra — 2025-01-07

Migraine is a neurological condition often presenting as severe, pulsating headaches on one side of the brain. These episodes can last hours or days, significantly interfering with daily activities. This study aimed to evaluate the prevalence, identify triggers, and classify them among migraine patients. A prospective study was conducted in the Neurology Outpatient Department of KIMS Hospital, Nellore, over six months (November 2024 to May 2025). Data were collected via a specially designed questionnaire to obtain baseline information.Results: The study included 103 patients, with 82 (79.6%) females and 21 (20.4%) males. Among them, 61 (59.2%) reported migraines lasting years, 26 (25.2%) for months, and 16 (15.6%) for days. Duration of headache episodes varied, with 64 (62.1%) experiencing headaches for hours, 23 (22.3%) for minutes, and 16 (15.6%) for days. The prevalence rate was 51.5%. Patients identified various triggers, which were classified accordingly.Conclusion: The prevalence of migraines was 51.5%, highlighting a significant burden of this condition. Despite its impact, limited awareness persists. Recognizable triggers identified by patients can guide tailored treatment adjustments. This study equips primary care physicians with valuable insights to educate patients and develop effective management strategies, ultimately improving the quality of life for individuals suffering from migraines.

Investigation of in-vitro anti-inflammatory activity of oxalis latifolia kunth whole plant

Neelima S — 2025-01-05

The primary purpose of the current study was to assess the invitro anti-inflammatory effects of methanolic extract of Oxalis latifolia Kunth (MEOL) using bovine serum and egg albumin protein denaturation method. In this method, anti-inflammatory was evaluated for the methanolic extract of Oxalis latifolia kunth (MEOL) whole plant and standard (Diclofenac sodium) at varying concentrations (100 - 500?g/ml). The bovine serum & egg albumin protein denaturation technique assessed MEOL for its anti-inflammatory activity. In both methods, it was found that an increase in the concentration of MEOL showed growth in the percentage of inhibition. The MEOL activity was compared to standards such as Diclofenac sodium. In this, it was evident that an increase in the concentration MEOL increased's anti-inflammatory activity of MEOL through inhibition of bovine serum & egg albumin protein denaturation. From the results, it was concluded that MEOL whole plant proved to have anti-inflammatory action by inhibiting bovine serum & egg albumin protein denaturation.